Certolizumab pegol

PheWeb

RX_L04AB05

No definition available.

Endpoint definition

↥

FinnGen phenotype data

321302 individuals

Apply sex-specific rule None

321302

Check conditions None

321302

Filter registries

Medicine purchases: ATC L04AB05

353

Check pre-conditions, main-only, mode, ICD version None

281

Check minimum number of events

Min. number of events 3

281

Include endpoints None

281

RX_L04AB05

Extra metadata

First used in FinnGen datafreeze DF4

Similar endpoints

↥

List of similar endpoints to Certolizumab pegol based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	270	209	61
Unadjusted prevalence (%)	0.09	0.12	0.05
Mean age at first event (years)	47.64	47.03	49.74

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	-	-	-	-
15 years	-	-	-	-
5 years	-	-	-	-
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: RX_L04AB05 – Certolizumab pegol
GWS hits:

Survival analyses between endpoints

↥

Plot

before Certolizumab pegol
after Certolizumab pegol

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Certolizumab pegol

↥